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Objective: Coal tar ointments are used as treatment of various skin diseases, especially psoriasis and eczema. These ointments contain
several carcinogenic polycyclic aromatic hydrocarbons. Metabolites of these polycyclic aromatic hydrocarbons are excreted in the urine and
therefore, dermatological use of coal tar may be associated with an increased risk of bladder cancer. The objective of this study was to
evaluate the association between dermatological use of coal tar ointments and bladder cancer.
Material and methods: A population-based case-control study was conducted including 1,387 cases diagnosed with bladder cancer and
5,182 population controls. Information on the use of coal tar, history of skin disease, and known risk factors for bladder cancer was obtained
through postal questionnaires. Logistic regression analyses were performed to estimate the risk of bladder cancer after coal tar treatment,
adjusted for age, gender, smoking status, duration of smoking, and intensity of smoking.
Results: The use of coal tar ointments was approximately equal among cases and controls (3.8% vs. 3.0%, respectively). Dermatological
application of coal tar was not signiﬁcantly associated with bladder cancer (adjusted odds ratio ¼ 1.37, 95% CI: 0.93–2.01). An inverse
association between bladder cancer and a history of skin disease was observed (adjusted odds ratio ¼ 0.74, 95% CI: 0.61–0.90).
Conclusion: This is the ﬁrst study with a speciﬁc aim to study the association between the use of coal tar preparations and bladder
cancer. The results suggest that there is no reason for safety concerns with respect to the risk of bladder cancer after the use of coal tar
preparations in dermatological practice. r 2014 Elsevier Inc. All rights reserved.
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Coal tar is an effective therapy in the treatment of
chronic skin diseases, such as psoriasis and eczema [1]. It
contains more than 10,000 compounds, including polycy-
clic aromatic hydrocarbons (PAHs), in high concentrations.
Some PAH, such as benzo(a)pyrene are classiﬁed as human
carcinogens [2,3]. Because of the carcinogenic potency of
PAHs, concerns have been raised about the risk of cancer
after coal tar treatment in patients with skin diseases. The
skin is an important route of uptake after dermatologicalmatter r 2014 Elsevier Inc. All rights reserved.
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iemeney@radboudumc.nl (L.A.L.M. Kiemeney).exposure to coal tar [4]. Several studies have therefore
investigated the risk of skin cancer after coal tar treatment
but most studies [5–8], except one of Stern et al. [9], did not
observe an increased risk. After application, coal tar is
absorbed and metabolized in the skin and body. After
metabolization, several metabolites of PAHs are excreted in
the urine [10]. Therefore, dermatological use of coal tar
might be associated with an increased risk of nonskin
cancer, especially bladder cancer. The risk of nonskin
cancer in patients treated with coal tar was investigated in
only a few studies and most of these studies did not observe
an increased risk of internal malignancies [6,11–13]. How-
ever, none of the previously performed studies had a
speciﬁc aim to test the association between bladder cancer
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this case-control study, we examined the risk of bladder
cancer after exposure to coal tar ointments used in the
dermatological practice.Table 1
Characteristics of the study population
Cases
(n ¼ 1,387)
Controls
(n ¼ 5,182)
Age at completion of the questionnaire, ya 67.3  9.4 57  16
Gender (% men) 84 46
Smoking status
Never smokers, % 10.7 36.2
Former smokers, % 64.9 47.6
Number of cigarettes, cigarettes/da 15.4  4.5 12.6  8.7
Smoking duration, ya 29.2  13.7 20.4  13.6
Age at start smoking, ya 17.5  4.5 17.7  4.6
Current smokers, % 24.4 16.2
Number of cigarettes, cigarettes/da 15.3  5.1 13.7  8.1
Smoking duration, ya 42.7  13.1 32.1  15.2
Age at start of smoking, ya 17.6  5.1 17.4  5.0
Educational level, %
Primary school 15.9 7.2
Technical/professional school 52 53.1
Secondary school 22.3 21.9
University degree 9.8 17.8
Use of temporary or permanent dyes
or both, %
13.9 44.9
Skin disease, % 14.4 18.8
Use of coal tar ointments, % 3.8 3.0
aMean  standard deviation.2. Material and methods
2.1. Study population and data collection
Patients were identiﬁed by the Department of Registry
and Research of the Comprehensive Cancer Centre, Nijme-
gen, the Netherlands. All patients with bladder cancer
who were diagnosed between 1995 and 2006, younger than
75 years, in this region, and alive at time of data collection
were invited to participate in a study on genetic suscepti-
bility and environmental risk factors for bladder cancer
[14]. Patients ﬁlled out a detailed postal questionnaire
concerning topics such as demographic factors, life style,
history of diseases (e.g., cancer), and medication use. The
response rate was 62%. For the current study, only bladder
cancer cases with urothelial cell carcinoma were included
(n ¼ 1,501). Patients with missing data on skin disease,
smoking status, or use of coal tar ointments were excluded
(n ¼ 114). A total of 1,387 cases were included in the
analyses.
Controls were obtained through the Nijmegen Biomed-
ical Study, a population-based survey conducted by the
Radboud University Medical Centre in 2002 [15]. A
random selection of inhabitants of Nijmegen were invited
to participate in a study on risk factors for (any) disease by
ﬁlling out a detailed postal questionnaire. In 2008, an
additional questionnaire, more speciﬁcally aimed at poten-
tial risk factors for bladder cancer was sent to all partic-
ipants of the Nijmegen Biomedical Study who gave consent
for further research and were still alive then. A total of
5,613 (64%) persons returned this second questionnaire.
Persons who were diagnosed with cancer (except for basal
cell carcinomas of the skin) at the time of data collection
were excluded (n ¼ 303), as well as controls with missing
data on smoking status and skin disease (n ¼ 128). Coal tar
exposure was measured as “yes” vs. “no.” People with
missing data on this variable (n ¼ 1,481) were included in
this category as well (assuming that persons who did not
answer yes to this question did not use these preparations).
A total of 5,182 controls were included in the analyses. All
patients and controls gave written informed consent. The
study was approved by the Institutional Review Board of
the Radboud University Medical Centre.
2.2. Statistical analysis
Descriptive analyses were performed to provide insight
into the characteristics of the patients and controls. Logistic
regression analyses were performed to estimate odds ratios
(ORs) and 95% CI for the association between the use ofcoal tar ointments and bladder cancer. These analyses were
adjusted for age at completion of the questionnaire, gender,
and smoking. Smoking and male gender are strong risk
factors for bladder cancer. To exclude the effect of smoking
in the association between coal tar and bladder cancer,
subanalyses in nonsmokers were performed. In addition,
subanalyses in men and women were performed. We also
analyzed the association between occurrence of skin disease
and bladder cancer because coal tar ointments are applied in
patients with skin diseases. Models were not adjusted for
height, weight, use of temporary or permanent hair dyes or
both, and educational level because these variables did not
alter the effect estimates in the models. All statistical
analyses were performed in SAS (SAS system for Win-
dows, version 9.2, SAS institute, Cary, NC).3. Results
This study included 1,387 patients and 5,182 controls
(Table 1). Patients were older at the time of completing the
questionnaire compared with controls (67 y vs. 57 y).
Smoking, both current and former, was more frequent in
patients. Among current and former smokers, the patients
had smoked for a longer period of time and the intensity of
smoking was higher. Education level among patients was
lower compared with controls. The use of coal tar ointments
was approximately equal in both groups (3.8% vs. 3.0%).
Among individuals exposed to coal tar, skin diseases were
Table 2
Risk of bladder cancer associated with use of coal tar ointments and
occurrence of skin disease
Coal tar Skin disease
OR (95% CI) OR (95% CI)
Alla 1.37 (0.93–2.01) 0.74 (0.61–0.90)
Genderb
Male 1.32 (0.85–2.05) 0.68 (0.54–0.85)
Female 1.57 (0.72–3.39) 1.05 (0.70–1.58)
Never smokersc 1.20 (0.41–3.53) 1.08 (0.68–1.72)
aOR were adjusted for age at completing the questionnaire, gender,
smoking status, duration of smoking (in y), and intensity of smoking
(cigarettes/d).
bOR were adjusted for age at completing the questionnaire, smoking
status, duration of smoking (in y), and intensity of smoking (cigarettes/d).
cOR were adjusted for age at completing the questionnaire and gender.
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exposed (94% vs. 16.4%) (data not shown).
The risk of bladder cancer associated with exposure to
coal tar ointments is presented in Table 2. The use of coal
tar was not signiﬁcantly associated with bladder cancer
(OR ¼ 1.37, 95% CI ¼ 0.93–2.01). The strength of the
association was comparable among men and women. The
OR in the subgroup of nonsmokers was comparable to the
total group (OR ¼ 1.20 vs. 1.37), but this result was based
on small numbers (n ¼ 4 nonsmoking cases).
An inverse association between skin disease and bladder
cancer was observed (OR ¼ 0.74, 95% CI ¼ 0.61–0.90)
(Table 2), although this inverse association was restricted to
men (OR men ¼ 0.68, 95% CI: 0.54–0.85; OR women ¼
1.05, 95% CI: 0.70–1.58).4. Discussion
This is the ﬁrst population-based case-control study
speciﬁcally aimed at assessing the risk of bladder cancer
after dermatological use of coal tar. No association between
dermatological exposure to coal tar and bladder cancer was
observed. Several studies have shown that occupational
exposure to PAHs is associated with an increased risk of
bladder cancer [2,3,16]. The increased bladder cancer risk
in occupational studies was observed in workers with
prolonged occupational exposure, whereas dermatological
use of coal tar is most often limited to a much shorter
duration of exposure [10,17]. The results from the present
case-control study are in accordance with the results found
in some other studies, although these studies did not
speciﬁcally address the risk of bladder cancer [6,11–13].
Differences in cancer risks between occupational studies
and studies in patients may be explained by the duration of
PAH exposure. Possibly, the body is capable of repairing
tissue damage following short-term exposure to PAH but
not to the same extent after long-term exposure.We also investigated the association between bladder
cancer and skin diseases. An inverse association between
the occurrence of skin disease and bladder cancer was
observed, although it was restricted to men. It is difﬁcult to
explain this observed association because no information on
the type of skin disease was available from the question-
naires. However, it can be assumed that the major part of
the reported skin diseases will be eczema followed by
psoriasis. In both skin diseases, a hyperreactive immune
system leads to chronic inﬂammation. In eczema, it has
been hypothesized that this hyperreactive state may lead to
increased tumor immunosurveillance, which may decrease
the probability of proliferation of aberrant cells and there-
fore decreases the probability to develop malignancies
[18,19]. Several studies have evaluated the risk of bladder
cancer in patients with psoriasis or eczema, but they showed
conﬂicting results [5,6,20–22]. Several patients in these
studies had been treated with systemic therapies and as a
result, it is not possible to exclude the effect of these
therapies on the risk of cancer. In future research, it is
worthwhile to only include patients with 1 type of skin
disease to study the association between skin disease and
bladder cancer.
It is known that cigarette smoking is the most impor-
tant risk factor for bladder cancer [23]. In our study,
detailed information on smoking (duration of smoking
and intensity of smoking) was collected from the question-
naires and therefore we were able to adjust for smoking
in our analyses. Another important risk factor for bladder
cancer is occupational exposure to speciﬁc chemical
substances, such as aromatic amines and PAHs [23]. Data
on the occupational history of all patients and controls
were not readily available and as a consequence our
regression models were not adjusted for occupational
exposure.
Information was assessed after the diagnosis of bladder
cancer and therefore, recall bias cannot be excluded. We
assume that recall is limited because questions on these
topics were part of a questionnaire with a wide spectrum of
questions and we have no reason to assume that patients or
controls associate the use of coal tar or occurrence of skin
disease with the development of bladder cancer. No
information on the type and duration of coal tar preparations
was asked in the questionnaires. In dermatological practice
pix lithantracis and liquor carbonis detergens are used. Pix
lithantracis contains far more PAHs than liquor carbonis
detergens. In a large cohort study on the risk of cancer after
coal tar treatment that we conducted previously, no differ-
ences in cancer risk were observed between the use of pix
lithantracis and liquor carbonis detergens [13]. In the
present study, it was not possible to conﬁrm these results
because information on the type of coal tar preparations was
not collected.
We conclude that there is no reason for safety concerns
with respect to the risk of bladder cancer after the use of
coal tar preparations in dermatological practice.
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